Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease

BACKGROUND: Nonadherence to biologic therapy in inflammatory bowel disease (IBD) is associated with risk of relapse, immunogenicity, and disease complications. Significant nonadherence prevalence is reported with tumor necrosis factor (TNF) antagonists but the risk of nonadherence with newer biologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Anand, Kim, Emilie S, Kozan, Philip, Jacob, Vinita, Longman, Randy S, Scherl, Ellen J, Battat, Robert J, Lukin, Dana J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802380/
https://www.ncbi.nlm.nih.gov/pubmed/36777752
http://dx.doi.org/10.1093/crocol/otaa074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802380/
https://www.ncbi.nlm.nih.gov/pubmed/36777752
http://dx.doi.org/10.1093/crocol/otaa074

Ejemplares similares